← Back to Search

Signal Processing Strategy

Hearing Aid Signal Processing for Alzheimer's Disease

N/A
Recruiting
Led By Pam Souza, PhD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Normal or corrected to normal vision (20/40 binocular vision or unaided using a Snellen chart)
Sensorineural hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 500 and 3000 Hz and a 4 frequency (.5, 1, 2, 3 kHz) pure-tone average of greater than or equal to 30 dB in each ear
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to final appointment in each hearing aid condition will be assessed. participants will take an unaided baseline at the start of the trial. measure will be repeated at the end of each intervention (3-5 weeks after each fitting).
Awards & highlights

Study Summary

This trial is testing different signal processing strategies for hearing aids to see which one works better for people with Alzheimer's dementia.

Who is the study for?
This trial is for older adults with Alzheimer's dementia or its precursor, amnestic mild cognitive impairment. Participants must speak English, have normal vision or corrected-to-normal vision, sensorineural hearing loss within specific parameters, and a certain level of cognitive function. They should live at home and be able to consent to the study.Check my eligibility
What is being tested?
The study tests two types of signal manipulation in hearing aids: one with high levels of alteration and another with low levels. It aims to determine which strategy benefits those with Alzheimer's dementia more by providing clearer sound without too much processing.See study design
What are the potential side effects?
Since this trial involves non-invasive interventions related to hearing aid technology, side effects are minimal but may include discomfort from wearing the devices or challenges adapting to new auditory experiences.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My vision is normal or corrected to normal (20/40).
Select...
I have moderate hearing loss in both ears.
Select...
I have been diagnosed with Alzheimer's or mild memory loss with a MoCA score of at least 18.
Select...
I am capable of understanding and giving my consent for treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to final appointment ineach hearing aid condition will be assessed. participants will take an unaided baseline at the start of the trial. measure will be repeated at the end of each intervention (3-5 weeks after each fitting).
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to final appointment ineach hearing aid condition will be assessed. participants will take an unaided baseline at the start of the trial. measure will be repeated at the end of each intervention (3-5 weeks after each fitting). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change In Speech Intelligibility (%Correct)
Change in Conversation Analysis of Communication Breakdown

Trial Design

2Treatment groups
Experimental Treatment
Group I: Hearing Aid Fitting Order BExperimental Treatment2 Interventions
Participants wear hearing aids with a low level of signal manipulation, followed by a high level of signal manipulation
Group II: Hearing Aid Fitting Order AExperimental Treatment2 Interventions
Participants wear hearing aids with a high level of signal manipulation, followed by a low level of signal manipulation

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,580 Previous Clinical Trials
916,827 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
327 Previous Clinical Trials
178,296 Total Patients Enrolled
Pam Souza, PhDPrincipal InvestigatorNorthwestern University

Media Library

Alzheimer's Dementia Research Study Groups: Hearing Aid Fitting Order A, Hearing Aid Fitting Order B
Alzheimer's Dementia Clinical Trial 2023: High level of signal manipulation Highlights & Side Effects. Trial Name: NCT04240561 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research program have any open slots for interested participants?

"Affirmative. Clinicaltrials.gov records signify that this clinical trial, initially posted on July 1st 2021 is currently enrolling participants. 20 patients have to be recruited from 2 clinics."

Answered by AI

What qualifications must an individual possess to be eligible for this research project?

"This clinical trial is seeking 20 participants between 50 and 90 years of age who have cochlear hearing loss. Furthermore, these patients must possess a Clinical Dementia Rating (CDR) score indicating slight or mild cognitive impairment, a diagnosis of dementia Alzheimer's type or amnestic mild cognitive impairment with at least MoCA score of 18, normal or corrected to normal vision able to be tested via Snellen chart, sensorineural hearing loss ranging from 25-70 dB HL across octave frequencies 500 Hz - 3000 Hz with 4 frequency pure tone average greater than 30dB in each ear, minimum Grade 10 education level as well as the"

Answered by AI

Are elderly individuals eligible to join this clinical trial?

"According to the enrollment prerequisites, individuals must be aged 50 or above but below 90 in order to participate."

Answered by AI

What is the upper limit of individuals who are taking part in this clinical experiment?

"Yes, recent information from clinicaltrials.gov confirms that this medical research is actively searching for participants; it was initially posted on July 1st 2021 and has been updated as recently as September 26th 2022. Two sites are required to fill the 20 openings available in the trial."

Answered by AI
~0 spots leftby Mar 2024